T0	Participants 26 92	pancreatic cancer with epidermal growth factor receptor mutations:
T1	Participants 432 578	Eighty-eight chemotherapy-na√Øve metastatic pancreatic cancer patients were randomized for treatment with gemcitabine or gemcitabine plus erlotinib
T2	Participants 1175 1243	in patients with EGFR mutations than in those without EGFR mutations
T3	Participants 1399 1483	treating metastatic pancreatic cancer patients, especially those with EGFR mutations